Codexis faces a challenging outlook characterized by extreme revenue lumpiness, as evidenced by quarterly fluctuations between $7.5M and $38.9M, which complicates long-term operational planning. While the company maintains high gross margins often exceeding 80...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.13+8.2% vs -$0.14 | $15M+7.9% vs $14M |
Q2 2026 May 7, 2026 | -$0.10+9.1% vs -$0.11 | $15M+5.0% vs $15M |
Q2 2026 Mar 11, 2026 | $0.11+1000.0% vs $0.01 | $39M+8.6% vs $36M |
Q4 2025 Nov 6, 2025 | -$0.22-46.7% vs -$0.15 | $9M-76.0% vs $36M |
BlackRock Inc. bought a new stake in shares of Codexis, Inc. (NASDAQ: CDXS) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund bought 7,284,352 shares of the biotechnology company's stock, valued at approximately $16,463,000. BlackRock Inc. owned 8.01% of Codexis as of its most recent
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York.
Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
Benchmark CDXS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Codexis, Inc. (CDXS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.38 | $148.43M | -2.76 | 18.61% | -62.47% | -74.88% | — | |
| $1.45 | $352.95M | -10.36 | 849.33% | -119.93% | -50.64% | — | |
| $24.37 | $2.51B | -30.09 | 120.01% | -54.75% | -7.7% | — | |
| $45.69 | $2.68B | 12.35 | 77.36% | 19.84% | 11.01% | — | |
| $5.71 | $1.98B | -9.52 | 698.96% | -88.19% | -49.73% | — | |
| $3.02 | $329.76M | -1.50 | — | — | -5.76% | — |
Codexis, Inc. (CDXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Codexis, Inc. (CDXS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jul 27, 2026·SEC
Jul 23, 2026·SEC
Get notified when CDXS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Codexis, Inc. (CDXS) stock FAQ — growth, dividends, profitability & financials explained
Codexis, Inc. (CDXS) reported $77.7M in revenue for fiscal year 2025. This represents a 541% increase from $12.1M in 2006.
Codexis, Inc. (CDXS) grew revenue by 18.6% over the past year. This is strong growth.
Codexis, Inc. (CDXS) reported a net loss of $30.7M for fiscal year 2025.
Codexis, Inc. (CDXS) has a return on equity (ROE) of -74.9%. Negative ROE indicates the company is unprofitable.
Codexis, Inc. (CDXS) had negative free cash flow of $12.2M in fiscal year 2025, likely due to heavy capital investments.
